Last reviewed · How we verify
Mebadin (dihydroemetine)
Mebadin (generic name: dihydroemetine) is a dihydroemetine drug. It is currently in unknown development.
Mebadin works by inhibiting the growth and replication of certain parasites.
Mebadin (dihydroemetine) is a small molecule drug in the dihydroemetine class, but specific details about its development, commercial status, and approved indications are not available. As a dihydroemetine, it is likely used to treat certain parasitic infections. However, without further information, it is difficult to provide a comprehensive summary. Further research is needed to determine its target, pharmacokinetic properties, and safety considerations. It is unclear whether Mebadin is patented or available as a generic product.
At a glance
| Generic name | dihydroemetine |
|---|---|
| Drug class | dihydroemetine |
| Therapeutic area | Immunology |
| Phase | unknown |
Mechanism of action
Imagine your body as a city with a strong immune system that can fight off invaders. Mebadin is like a special kind of police officer that helps your immune system catch and eliminate the bad guys, in this case, parasites. By stopping the parasites from growing and multiplying, Mebadin helps your body recover from infection.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mebadin CI brief — competitive landscape report
- Mebadin updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Mebadin
What is Mebadin?
How does Mebadin work?
What is the generic name of Mebadin?
What drug class is Mebadin in?
What development phase is Mebadin in?
Related
- Drug class: All dihydroemetine drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Immunology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing